A BILL 
To direct the Comptroller General of the United States to 
evaluate and report on the inpatient and outpatient 
treatment capacity, availability, and needs of the United 
States. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Examining Opioid 
4
Treatment Infrastructure Act of 2021’’. 
5
03:04 May 01, 2021
H1686
2 
•HR 1686 IH
SEC. 2. STUDY ON TREATMENT INFRASTRUCTURE. 
1
Not later than 24 months after the date of enactment 
2
of this Act, the Comptroller General of the United States 
3
shall initiate an evaluation of, and submit to Congress a 
4
report on, the inpatient and outpatient treatment capacity, 
5
availability, and needs of the United States, including, to 
6
the extent data are available— 
7
(1) the capacity of acute residential or inpatient 
8
detoxification programs; 
9
(2) the capacity of inpatient clinical stabiliza-
10
tion programs, transitional residential support serv-
11
ices, and residential rehabilitation programs; 
12
(3) the capacity of demographic specific resi-
13
dential or inpatient treatment programs, such as 
14
those designed for pregnant women or adolescents; 
15
(4) geographical differences of the availability 
16
of residential and outpatient treatment and recovery 
17
options for substance use disorders across the con-
18
tinuum of care; 
19
(5) the availability of residential and outpatient 
20
treatment programs that offer treatment options 
21
based on reliable scientific evidence of efficacy for 
22
the treatment of substance use disorders, including 
23
the use of Food and Drug Administration-approved 
24
medicines and evidence-based nonpharmacological 
25
therapies; 
26
03:04 May 01, 2021
H1686
3 
•HR 1686 IH
(6) the number of patients in residential and 
1
specialty outpatient treatment services for substance 
2
use disorders; 
3
(7) an assessment of the need for residential 
4
and outpatient treatment for substance use disorders 
5
across the continuum of care; 
6
(8) the availability of residential and outpatient 
7
treatment programs to American Indians and Alaska 
8
Natives through an Indian health program (as de-
9
fined by section 4 of the Indian Health Care Im-
10
provement Act (25 U.S.C. 1603)); and 
11
(9) the barriers (including technological bar-
12
riers) at the Federal, State, and local levels to real- 
13
time reporting of de-identified information on drug 
14
overdoses and ways to overcome such barriers. 
15
Æ 
03:04 May 01, 2021
H1686
